Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.
As Genfit SA prepares to shift from a clinical- to a commercial-stage company, Pascal Prigent was named the firm's new CEO on 2 September because he brings the right skill set to make the transition.
Prigent was recruited for the French biotech in May 2018, as executive VP of marketing and commercial development. His prior experience in marketing, sales and management at GlaxoSmithKline PLC...
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
